HPV Testing and Pap Test Global Market Report 2024

The hpv testing and pap test market has grown rapidly in recent years. It will grow from $4.08 billion in 2023 to $4.52 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The expansion observed during the historical period can be attributed to cervical cancer awareness campaigns, the implementation of screening programs, government initiatives and funding, advocacy for women's health, the heightened disease burden, and increased adherence to gynecological examination practices.

The hpv testing and pap test market is expected to see rapid growth in the next few years. It will grow to $6.91 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%. The anticipated growth in the forecast period can be attributed to vaccination programs, precision medicine approaches, the integration of molecular diagnostics, global health equity initiatives, dynamics related to an aging population, and policies related to reimbursement for diagnostic tests. Key trends expected in the forecast period encompass a shift towards HPV testing, the adoption of co-testing approaches, the increased use of molecular testing, automation in testing processes, and the availability of home-based testing options.

The HPV testing and Pap test markets are experiencing growth driven by an increase in the prevalence of cervical cancer. Cervical cancer, characterized by uncontrolled cell growth in the cervix, underscores the importance of early detection through methods such as HPV testing and Pap tests. In January 2023, the American Cancer Society reported an estimated 13,960 new cases of cervical cancer in the US, with approximately 4,310 expected deaths. This surge in cervical cancer cases is a significant factor propelling the HPV testing and Pap test market forward.

Anticipated growth in the HPV testing and Pap test market is also attributed to the rising geriatric population. As individuals age, preventive healthcare becomes a focal point, prompting regular screenings such as HPV testing and Pap smears for the early detection of cervical abnormalities. In October 2022, the World Health Organization (WHO) projected that one in six people globally would be 60 or older by 2030, with 2.1 billion individuals expected to fall into this age group by 2050. The increasing geriatric population is thus contributing to the expansion of the HPV testing and Pap test market.

A key trend in the HPV testing and Pap test markets is the introduction of product innovations by major companies aiming to sustain their market positions. In January 2022, Ghana-based biotechnology company Yemaachi Biotechnology launched the Sheba HPV Test, an efficient home sampling kit utilizing polymerase chain reaction (PCR) technology for the detection of human papillomavirus. This innovative solution identifies women at high risk of cervical cancer.

Major companies in the HPV testing and Pap test market are also focusing on developing self-sampling solutions to cater to a broader customer base, increase sales, and boost revenue. Self-sampling involves individuals collecting samples independently, without the direct involvement of external professionals. In June 2022, Swiss pharmaceutical company F. Hoffmann-La Roche AG introduced an HPV self-sampling solution, allowing patients to privately collect vaginal samples for HPV screening within healthcare facilities under healthcare worker guidance. The self-collected samples undergo analysis using the Roche Cobas HPV test, demonstrating test performance comparable to samples collected traditionally by clinicians.

In November 2022, Quest Diagnostics, a US-based medical laboratories company, acquired the outreach laboratory services business of Summa Health. This acquisition extends Quest's diagnostic innovation reach and enhances health outcomes in Northeastern Ohio communities. Summa Health, a provider of HPV and Pap tests, offers physicians and patients access to Quest's advanced test menu, extensive patient access sites, comprehensive health plan coverage, and reduced out-of-pocket costs for various services, ultimately contributing to improved healthcare in the region.

Major companies operating in the hpv testing and pap test market report are Abbott Laboratories, Qiagen N.V., Becton Dickinson and Company, Quest Diagnostics Inc., Hologic Inc., F. Hoffmann-La Roche AG, Femasys Inc., Arbor Vita Corporation, NURX Inc., Seegene Inc., Thermo Fisher Scientific Inc., BioMérieux SA, Onco Health Corporation, Takara Bio Inc., TruScreen Group Limited, Danaher Corporation, Mylab Discovery Solutions Pvt. Ltd., Fujirebio Diagnostics Inc., Promega Corporation, Myriad Genetics Inc., DiaSorin S.p.A., Genomica S.A.U., Grifols S.A., Illumina Inc., Inovio Pharmaceuticals Inc., Merck & Co. Inc., Novartis AG, Pfizer Inc., Quidel Corporation, Randox Laboratories Ltd., Siemens Healthineers AG, Trovagene Inc., Vela Diagnostics, Zymo Research Corp., CerviCusco.

North America was the largest region in the HPV testing and Pap test market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global HPV testing and Pap tests market report during the forecast period. The regions covered in the hpv testing and pap test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hpv testing and pap test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of HPV testing and Pap tests include, unsurprisingly, HPV testing and Pap tests. HPV testing involves healthcare providers checking for the presence of the human papillomavirus (HPV) in a patient's body. The main products associated with these tests include instruments, consumables, and services utilizing technologies such as polymerase chain reaction (PCR), immunodiagnostics, and other relevant technologies. These screening methods find application in cervical cancer screening and vaginal cancer screening and are commonly employed by hospitals, clinics, laboratories, and various other end users.

The HPV testing and Pap tests market research report provides HPV testing and Pap tests market statistics, including global market size, regional shares, competitors with a HPV testing and Pap tests market share, detailed HPV testing and Pap tests market segments, market trends and opportunities, and any further data you may need to thrive in the HPV testing and Pap tests industry. This HPV testing and Pap tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The HPV testing and Pap test market consist of revenues earned by entities by conventional Pap test, liquid-based Pap test, HPV DNA test and co-testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The HPV testing and Pap test market also consist of sales of HPV testing and Pap test kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.